| 000 | 01107 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250517111058.0 | ||
| 264 | 0 | _c20170411 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a1477-0962 | ||
| 024 | 7 |
_a10.1177/0961203316652489 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDurcan, L | |
| 245 | 0 | 0 |
_aWhy targeted therapies are necessary for systemic lupus erythematosus. _h[electronic resource] |
| 260 |
_bLupus _cSep 2016 |
||
| 300 |
_a1070-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aInterferon-alpha _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xdrug therapy |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 | _aPrecision Medicine |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 700 | 1 | _aPetri, M | |
| 773 | 0 |
_tLupus _gvol. 25 _gno. 10 _gp. 1070-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/0961203316652489 _zAvailable from publisher's website |
| 999 |
_c26302900 _d26302900 |
||